PRMT5 and lymphoma: In vivo studies with GSK-591 are limited due to its poor pharmacological properties13, we evaluated the in vivo efficacy of PRMT5 inhibition using the close analog GSK-025, because of its equivalent mechanism of action and cytotoxic activity in vitro in all lymphoma cell lines tested22.